Baltazar Gomez-Mancilla, MD, PhD

  • 2Articles
  • 6.2KReads1
  • 2014–2025Active
  • 20Collaborators
  • 46Citations2

About

Baltazar Gomez-Mancilla, MD, PhD, is affiliated with Novartis Biomedical Research in Cambridge, Massachusetts, Novartis Pharma AG in Basel, Switzerland, and McGill University in Montreal, Québec, Canada. His publications focus on psychiatry, specifically major depressive disorder and treatment-resistant depression, as well as rare diseases such as Fragile X syndrome. His work includes clinical studies on novel pharmacological agents and reviews on translating molecular research into therapeutic strategies.

Publications

JCP
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
Original Research

Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study

August 6, 2025

Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
, , , et al
JCP
Review Article

Translating Molecular Advances in Fragile X Syndrome Into Therapy: A Review

April 15, 2014

, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe